Most popular peptides in Australia

Public attention is the biggest contributor to its position, 39,578 people looked it up last month. That source supplies 27% of its score, the other three supply the rest.

Graded S tier by reptides.co, 189 publications indexed in Europe PMC, 34 trials registered on ClinicalTrials.gov. Counts describe the literature that mentions this compound, not evidence that it works.

Regulatory status: Not FDA-approved.

Published research is the biggest contributor to its position, 69 papers in the past twelve months against 35 the year before. That source supplies 41% of its score, the other three supply the rest.

Graded A tier by reptides.co, 1,412 publications indexed in Europe PMC, 18 trials registered on ClinicalTrials.gov. Counts describe the literature that mentions this compound, not evidence that it works.

Regulatory status: In FDA's updated April 22 2026 503A categories document, BPC-157 was removed from category 2 because the nominations were withdrawn, and FDA says it intends to consult the PCAC on July 23 2026 regardi In FDA's updated April 22 2026 503A categories document, TB-500 (thymosin beta-4 fragment) was removed from category 2 because the nomination was withdrawn, and FDA says it intends to consult the PCAC

Its S-tier evidence grade is the biggest contributor to its position. That source supplies 30% of its score, the other three supply the rest.

Graded S tier by reptides.co, 129 publications indexed in Europe PMC, 23 trials registered on ClinicalTrials.gov. Counts describe the literature that mentions this compound, not evidence that it works.

Regulatory status: FDA-approved (Egrifta 2010, Egrifta SV 2014, Egrifta WR March 2025).

Public attention is the biggest contributor to its position, 22,422 people looked it up last month. That source supplies 39% of its score, the other three supply the rest.

Graded A tier by reptides.co, 236 publications indexed in Europe PMC, 3 trials registered on ClinicalTrials.gov. Counts describe the literature that mentions this compound, not evidence that it works.

Regulatory status: In FDA's updated April 22 2026 503A categories document, BPC-157 was removed from category 2 because the nominations were withdrawn, and FDA says it intends to consult the PCAC on July 23 2026 regardi

Public attention is the biggest contributor to its position, 13,685 people looked it up last month. That source supplies 38% of its score, the other three supply the rest.

Graded B tier by reptides.co, 3,092 publications indexed in Europe PMC, 207 trials registered on ClinicalTrials.gov. Counts describe the literature that mentions this compound, not evidence that it works.

Regulatory status: NAD+ and its precursors are not FDA-approved drugs for anti-aging, fatigue, cognition, or longevity.

Its S-tier evidence grade is the biggest contributor to its position. That source supplies 39% of its score, the other three supply the rest.

Graded S tier by reptides.co, 111 publications indexed in Europe PMC, 2 trials registered on ClinicalTrials.gov. Counts describe the literature that mentions this compound, not evidence that it works.

Regulatory status: In FDA's updated April 22 2026 503A categories document, injectable GHK-Cu was removed from category 2 because the nominations were withdrawn, and FDA says it intends to consult the PCAC before the en

Public attention is the biggest contributor to its position, 13,450 people looked it up last month. That source supplies 41% of its score, the other three supply the rest.

Graded A tier by reptides.co, 104 publications indexed in Europe PMC, 2 trials registered on ClinicalTrials.gov. Counts describe the literature that mentions this compound, not evidence that it works.

Regulatory status: Neither CJC-1295 nor ipamorelin is FDA-approved.

Published research is the biggest contributor to its position, 46 papers in the past twelve months against 29 the year before. That source supplies 38% of its score, the other three supply the rest.

Graded A tier by reptides.co, 260 publications indexed in Europe PMC, 29 trials registered on ClinicalTrials.gov. Counts describe the literature that mentions this compound, not evidence that it works.

Regulatory status: FDA approved Forzinity (elamipretide) for Barth syndrome on September 19, 2025, specifically to improve muscle strength in adult and pediatric patients weighing at least 30 kg.

Published research is the biggest contributor to its position, 58 papers in the past twelve months against 45 the year before. That source supplies 46% of its score, the other three supply the rest.

Graded B tier by reptides.co, 274 publications indexed in Europe PMC, 4 trials registered on ClinicalTrials.gov. Counts describe the literature that mentions this compound, not evidence that it works.

Regulatory status: In FDA's updated April 22 2026 503A categories document, MOTS-c was removed from category 2 because the nomination was withdrawn, and FDA says it intends to consult the PCAC on July 23 2026 regarding

Public attention is the biggest contributor to its position, 16,317 people looked it up last month. That source supplies 78% of its score, the other three supply the rest.

Graded B tier by reptides.co, 232 publications indexed in Europe PMC, 0 trials registered on ClinicalTrials.gov. Counts describe the literature that mentions this compound, not evidence that it works.

Regulatory status: Registered in Russia for ischemic stroke and selected neurocognitive or ophthalmic indications. Registered in Russia since 2009 for generalized anxiety disorder and neurasthenia.